Citations

Clear

6273 citation(s) found for "To, Andrew".

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu, Zhuxuan , Irvin, Sarah , Anton‐Culver, Hoda , Beckmann, Matthias W. , Chang‐Claude, Jenny, Cook, Linda , Cushing‐Haugen, Kara L. , Fasching, Peter A. , Gayther, Simon A. , Giles, Graham G. , Goode, Ellen L. , Kaaks, Rudolf , Kotsopoulos, Joanne , Le, Nhu D. , Matsuo, Keitaro , McGuire, Valerie, McLaughlin, John R, Menon, Usha , Moysich, Kirsten B. , Pearce, Celeste Leigh , Pike, Malcolm C. , Ramus, Susan J. , Riggan, Marjorie J. , Rothstein, Joseph H. , Schildkraut, Joellen M. , Sieh, Weiva , Sutphen, Rebecca , Terry, Kathryn L. , Thompson, Pamela J., Titus, Linda , Altena, Anne M. van , White, Emily, Whittemore, Alice S. , Wu, Anna H. , Wentzensen, Nicolas , Group, AOCS, Risch, Harvey A. , Modugno, Francesmary , Zheng, Wei , Anton-Culver, Hoda , Giles, Graham G , Kaaks, Rudolf , Kotsopoulos, Joanne , Matsuo, Keitaro , Menon, Usha , Ramus, Susan J , Sieh, Weiva , van Altena, Anne M , Ziogas, Argyrios , Wentzensen, Nicolas , Risch, Harvey A , Modugno, Francesmary , Moysich, Kirsten , Zheng, Wei , Fu, Zhuxuan , Goodman, Marc T , Brooks, Maria M. , Jordan, Susan J. , Aben, Katja K.H. , Bandera, Elisa V. , Berchuck, Andrew , Brooks‐Wilson, Angela , Cook, Linda S, Cramer, Daniel W. , Doherty, Jennifer A. , Ekici, Arif B. , Fortner, Renée T. , Gentry‐Maharaj, Aleksandra , Goodman, Marc T. , Harris, Holly R. , Hein, Alexander , Kiemeney, Lambertus A. , Köbel, Martin , Lee, Alice W. , McLaughlin, John R, Milne, Roger L. , Qin, Bo , Zheng, Wei , Ziogas, Argyrios , Taylor, Sarah E , Tang, Lu , Songer, Thomas J. , Webb, Penelope M. , Group, AOCS

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 23, 2023 | Volume: 115 | Issue: 5 | Pages: 539-551

10.1093/jnci/djad011 | PMID 36688720 Get It

Abstract Background The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. Methods LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. Results LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. Conclusions LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.
Fetal surgery is not associated with increased inflammatory placental pathology
Cárdenas, María C. , Cheek‐Norgan, E. Heidi, Norgan, Andrew P. , Schenone, Mauro , Lemens, Maureen A. , Chakraborty, Rana , Ruano, Rodrigo , Enninga, Elizabeth Ann L. , Branda, Megan E. , Ruano, Rodrigo , Enninga, Elizabeth Ann L , Norgan, Andrew P , Schenone, Mauro H

Mayo Clinic

Prenatal Diagnosis | January 23, 2023 | Volume: 43 | Issue: 3 | Pages: 382-392

10.1002/pd.6319 | PMID 36688485 Get It

AbstractObjectiveFetal surgery has improved neonatal outcomes; however, it is unknown if the intervention contributes to the developmental of inflammatory pathologies in the placenta. Here, an association between fetal surgery and placental pathology was examined.MethodThis case‐control study compared pregnancies with fetal surgery (n = 22), pregnancies with an indication for fetal surgery but without an intervention being done (n = 13), and gestational‐age and fetus‐number matched controls (n = 36). Data on maternal, infant, and placental outcomes were abstracted. Additionally, immunohistochemistry identified expression of lymphoid and myeloid cells in the placenta on a subset of cases. Comparisons were performed using Kruskal‐Wallis or Pearson's chi‐squared tests.ResultsMaternal characteristics were comparable between groups. Most fetal interventions were for diaphragmatic hernia, spina bifida, or twin‐to‐twin transfusion syndrome. Fetuses who were operated on before birth were more likely to be born preterm (p = 0.02). There was no increase in the rate of observed placental pathologies or immune cell infiltration in fetal surgery cases compared to controls.ConclusionThe data suggest that fetal surgery is not associated with increased inflammatory or morphologic pathology in the placenta. This observation supports the growing field of fetal surgery.
Safety of endoscopic ultrasound-guided tissue acquisition with uninterrupted direct oral anticoagulation in a swine model
Paredes, Ana García García de , Hartley, Christopher , Hernández-Lara, Ariosto H. , Pruthi, Rajiv K. , Gleeson, Ferga C. , Levy, Michael J. , Rajan, Elizabeth , Garcia Garcia de Paredes, Ana , AbiMansour, Jad P. , Valls, Eric J. Vargas, Hartley, Christopher P , Vargas, Eric J. , Graham, Rondell P. , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | January 19, 2023 | Volume: 11 | Issue: 04 | Pages: E413-E418

10.1055/a-2016-0160 | PMID 37124710 Get It

Abstract Background and study aims The risk of bleeding with endoscopic ultrasound-guided tissue acquisition (EUS-TA) in patients on uninterrupted antithrombotic agents is unknown. This study aimed to assess the safety of EUS-TA without discontinuing direct oral anticoagulants. Methods Twenty pigs were randomized (1:1) to oral apixaban or placebo. Treatment was administered for 3 days before and 3 days after EUS-TA of the pancreas. Primary endpoint was occurrence of clinically significant bleeding events (CSBEs), defined as a composite outcome of drop in hemoglobin ≥ 2 g/dL and evidence of intraprocedural or post-procedure bleeding. Secondary outcome was cytopathological adequacy of acquired specimens. Endoscopists and pathologists were blinded to the treatment arm. Results Total of 80 tissue samples were obtained. CSBE occurred in one animal with apixaban levels above the upper limit (P = 1). Intraprocedural bleeding occurred in five animals (25 %), four of which from the apixaban group. Hematoma at necropsy was found in 10 animals (50 %), six of which were on apixaban. Median drop in hemoglobin was similar in both groups. Adequacy of specimens for cytology and pathology evaluation was confirmed in 20 of 20 and 19 of 20 animals, respectively. Conclusions In this pilot preclinical trial, EUS-TA under apixaban showed a trend toward higher minor bleeding events but did not increase CSBE or prevent adequate cytopathological evaluation.
Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5‐Year Update
Tierney, William S. , Huang, Li‐Ching , Chen, Sheau‐Chiann , Berry, Lynn D., Anderson, Catherine , Benninger, Michael S. , Blumin, Joel H. , Bryson, Paul C. , Castellanos, Paul F., Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fink, Daniel S. , Franco, Ramon A. , Garrett, Catherine Gaelyn, Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Makani, Samir, Maldonado, Fabien , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , O’Dell, Karla , Postma, Gregory N. , Reder, Lindsay , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Daele, Douglas J. Van , Chen, Sheau-Chiann , Cohen, Seth M , Hoffman, Henry T , Weissbrod, Philip A , Amin, Milan R , Bock, Jonathan M. , Clary, Matthew S. , Guardiani, Elizabeth , Hillel, Alexander T. , Lott, David G. , Netterville, James L. , Ongkasuwan, Julina , Rohde, Sarah L. , Rohlfing, Matthew L. , Weinberger, Paul , Gelbard, Alexander

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 19, 2023 | Volume: 168 | Issue: 6 | Pages: 1570-1575

10.1002/ohn.190 | PMID 36939627 Get It

Abstract The North American Airway Collaborative (NoAAC) previously published a 3‐year multi‐institutional prospective cohort study showing variation in treatment effectiveness between 3 primary surgical techniques for idiopathic subglottic stenosis (iSGS). In this report, we update these findings to include 5 years of data evaluating treatment effectiveness. Patients in the NoAAC cohort were re‐enrolled for 2 additional years and followed using the prespecified published protocol. Consistent with prior data, prospective observation of 487 iSGS patients for 5 years showed treatment effectiveness differed by modality. Cricotracheal resection maintained the lowest rate of recurrent operation (5%), followed by endoscopic resection with adjuvant medical therapy (30%) and endoscopic dilation (50%). These data support the initial observations and continue to provide value to providers and patients navigating longitudinal decision‐making. Level of evidence: 2—prospective cohort study.
Fractionated plasma N‐glycan profiling of novel cohort of ATP6AP1‐CDG subjects identifies phenotypic association
Alharbi, Hana , Thies, Jenny , Chang, Irene J. , Goldner, Dana , Aqul, Amal , Velez‐Bartolomei, Frances , Enns, Gregory M. , Kichula, Elizabeth, Lee, Esther , Poskanzer, Sheri A. , Rasmussen, Sara K. , Saarela, Katelyn M. , Raymond, Kimiyo , Lam, Christina , Edmondson, Andrew C. , Lourenco, Charles , Poskanzer, Sheri A , Raymond, Kimiyo M, Freeze, Hudson H , Edmondson, Andrew C , Thies, Jenny M , Daniel, Earnest James Paul , Ng, Bobby G. , Witters, Peter , Hsu, Evelyn , Wang, YunZu Michele , Schultz, Matthew , Freeze, Hudson H. , He, Miao

Mayo Clinic

Journal of Inherited Metabolic Disease | January 18, 2023 | Volume: 46 | Issue: 2 | Pages: 300-312

10.1002/jimd.12589 | PMID 36651831 Get It

AbstractATP6AP1‐CDG is an X‐linked disorder typically characterized by hepatopathy, immunodeficiency, and an abnormal type II transferrin glycosylation pattern. Here, we present 11 new patients and clinical updates with biochemical characterization on one previously reported patient. We also document intrafamilial phenotypic variability and atypical presentations, expanding the symptomatology of ATP6AP1‐CDG to include dystonia, hepatocellular carcinoma, and lysosomal abnormalities on hepatic histology. Three of our subjects received successful liver transplantation. We performed N‐glycan profiling of total and fractionated plasma proteins for six patients and show associations with varying phenotypes, demonstrating potential diagnostic and prognostic value of fractionated N‐glycan profiles. The aberrant N‐linked glycosylation in purified transferrin and remaining plasma glycoprotein fractions normalized in one patient post hepatic transplant, while the increases of Man4GlcNAc2 and Man5GlcNAc2 in purified immunoglobulins persisted. Interestingly, in the single patient with isolated immune deficiency phenotype, elevated high‐mannose glycans were detected on purified immunoglobulins without glycosylation abnormalities on transferrin or the remaining plasma glycoprotein fractions. Given the diverse and often tissue specific clinical presentations and the need of clinical management post hepatic transplant in ATP6AP1‐CDG patients, these results demonstrate that fractionated plasma N‐glycan profiling could be a valuable tool in diagnosis and disease monitoring.
The Effects of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva: A Plain Language Summary
Pignolo, Robert J. , Mukaddam, Mona Al , Berglund, Staffan K. , Cheung, Angela M. , Cunto, Carmen De , Delai, Patricia , Haga, Nobuhiko , Mancilla, Edna E. , Marino, Rose , Strahs, Andrew, Cheung, Angela M , Hsiao, Edward C. , Baujat, Geneviève , Brown, Matthew , Kannus, Pekka , Keen, Richard , Sang, Kim‐Hanh Le Quan , Kaplan, Frederick S.

Mayo Clinic

Future Rare Diseases | January 18, 2023 | Volume: 3 | Issue: 1 | Pages: No page available

10.2217/frd-2022-0015 Get It

Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy
Frazee, Erin N. , Chang, Jack , Bjergum, Matthew W., Gajić, Ognjen, Jannetto, Paul J. , Mara, Kristin C. , Meade, Laurie A., Vollmer, Kathryn J., Scheetz, Marc H. , Group, For the BLOOM Study, Frazee, Erin N , Scheetz, Marc H , Mara, Kristin C , Gajic, Ognjen , Rule, Andrew D. , Group, For the BLOOM Study

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | January 17, 2023 | Volume: 43 | Issue: 11 | Pages: 1112-1120

10.1002/phar.2766 | PMID 36648390 Get It

AbstractStudy ObjectiveIn critically ill patients, adequacy of early antibiotic exposure has been incompletely evaluated. This study characterized factors associated with inadequate cefepime exposure in the first 24 h of critical illness.DesignProspective cohort study.SettingAcademic Medical Center.PatientsCritically ill adults treated with cefepime. Patients with acute kidney injury or treated with kidney replacement therapy or extracorporeal membrane oxygenation were excluded.InterventionNone.MeasurementsA nonlinear mixed‐effects pharmacokinetic (PK) model was developed to estimate cefepime concentrations for each patient over time. The percentage of time the free drug concentration exceeded 8 mg/L during the first 24 h of therapy was calculated (%ƒT>8; appropriate for the susceptible breakpoint for Pseudomonas aeruginosa). Factors predictive of low %ƒT>8 were explored with multivariable regression.Main ResultsIn the 100 included patients, a one‐compartment PK model was developed with first‐order elimination with covariates for weight and estimated glomerular filtration rate based on creatinine and cystatin C (eGFRSCr‐CysC). The median (interquartile range) %ƒT>8 for cefepime in the first 24 h of therapy based on this model was 85% (66%, 100%). Less than 100% ƒT>8 during first 24 h of therapy occurred in 70 (70%) individuals. Lower Sequential Organ Failure Assessment score (p = 0.032) and higher eGFRSCr‐CysC (p < 0.001) predicted a lower %ƒT>8. Central nervous system infection source was protective (i.e., associated with a higher %ƒT>8; p = 0.008).ConclusionsDuring early critical illness, cefepime concentrations were inadequate in a significant proportion of patients. Antimicrobial optimization is needed to improve the precision of pharmacotherapy in the critically ill patients.
GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients
Keddis, Mira T. , Howard, Matthew R., Galapia, Leyton, Frazee, Erin N. , Zhang, Nan , Butterfield, Richard , Rule, Andrew D.

Mayo Clinic

Nephrology Dialysis Transplantation | January 17, 2023 | Volume: 38 | Issue: 8 | Pages: 1898-1906

10.1093/ndt/gfad007 | PMID 36646435 Get It

ABSTRACT Background Serum cystatin C–based estimated glomerular filtration rate (eGFRcys) generally associates with clinical outcomes better than serum creatinine–based eGFR (eGFRcr) despite similar precision in estimating measured GFR (mGFR). We sought to determine whether the risk of adverse outcomes with eGFRcr or eGFRcys was via GFR alone or also via non-GFR determinants among kidney transplant recipients. Methods Consecutive adult kidney transplant recipients underwent a standardized GFR assessment during a routine follow-up clinic visit between 2011 and 2013. Patients were followed for graft failure or the composite outcome of cardiovascular (CV) events or mortality through 2020. The risk of these events by baseline mGFR, eGFRcr and eGFRcys was assessed unadjusted, adjusted for mGFR and adjusted for CV risk factors. Results There were 1135 recipients with a mean baseline mGFR of 55.6, eGFRcr of 54.8 and eGFRcys of 46.8 ml/min/1.73 m2 and a median follow-up of 6 years. Each 10 ml/min/1.73 m2 decrease in mGFR, eGFRcr or eGFRcys associated with graft failure [hazard ratio (HR) 1.79, 1.68 and 2.07, respectively; P &lt; .001 for all) and CV events or mortality outcome (HR 1.28, 1.19 and 1.43, respectively; P &lt; .001 for all). After adjusting for mGFR, eGFRcys associated with graft failure (HR 1.57, P &lt; .001) and CV events or mortality (HR 1.49, P &lt; .001), but eGFRcr did not associate with either. After further adjusting for CV risk factors, risk of these outcomes with lower eGFRcys was attenuated. Conclusion eGFRcr better represents the true relationship between GFR and outcomes after kidney transplantation because it has less non-GFR residual association. Cystatin C is better interpreted as a nonspecific prognostic biomarker than is eGFR in the kidney transplant setting.